成都先导(688222) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of RMB 426.99 million, a year-on-year increase of 14.99%[3] - Operating profit reached RMB 63.35 million, representing a significant year-on-year growth of 99.33%[8] - The total profit amounted to RMB 61.99 million, up 74.92% compared to the previous year[9] - Net profit attributable to the parent company was RMB 50.94 million, reflecting a year-on-year increase of 25.09%[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 55.37 million, a remarkable increase of 1,504.05%[9] - Basic earnings per share increased to RMB 0.13, up 27.13% from RMB 0.10 in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 1,761.27 million, a year-on-year increase of 1.83%[5] - Shareholders' equity attributable to the parent company was RMB 1,392.74 million, up 2.55% from the beginning of the period[5] Research and Development - The company focused on commercial projects and successfully advanced its self-developed pipeline HG146 to clinical phase II during the reporting period[6] - The company implemented a DMTA molecular optimization capability platform combining DEL and AI, which is expected to enhance drug discovery efficiency[7]